Efficacy of Automated Tuina and Acupuncture for Treating Chronic Lower Back Pain

November 15, 2026 updated by: Linda Zhong, Nanyang Technological University

Efficacy of Automated Tuina and Acupuncture for Treating Chronic Lower Back Pain: a Randomized Controlled Study

The goal of this clinical trial is to learn if adding automated robotic Tuina to acupuncture yields a better outcome than acupuncture alone in treating adults with chronic nonspecific low back pain. It will also learn about the safety of the automated robotic Tuina. The main questions it aims to answer are:

Does robotic Tuina and acupuncture reduces score of Visual Analogue Scale (VAS) more than acupuncture alone? Does it improve the sleep, quality of life, pain related impact of participants? Researchers will compare automated robotic Tuina and acupuncture to acupuncture alone if the combination works better to treat chronic nonspecific low back pain.

Participants will:

Receive weekly treatment of either automated robotic Tuina and acupuncture or acupuncture only for 6 sessions over 8 weeks.

Visit the clinic weekly for interventions and test. Wear a sleep tracker ring on the night before and night of treatment to sleep.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Chronic nonspecific low back pain is a common condition that can affect daily activities and quality of life. Tuina is a traditional Chinese medicine manual therapy that may help relieve pain and improve function. Automated robotic Tuina may offer a more standardized approach to delivering this treatment.

This randomized controlled study aims to evaluate whether adding automated robotic Tuina to acupuncture provides additional benefits for adults with chronic nonspecific low back pain, compared with acupuncture alone.

A total of 56 participants aged 21 to 70 years are planned for recruitment across three study sites in Singapore. Participants will be randomly assigned in a 1:1 ratio to receive either acupuncture alone or acupuncture combined with automated robotic Tuina.

The primary outcome is low back pain intensity measured using a visual analogue scale (VAS). Secondary outcomes include physical disability, pain-related interference, quality of life, sleep-related measures and acceptance of robotic Tuina. Adverse events will also be monitored throughout the study.

The findings may help clarify the additional clinical benefit and safety of automated robotic Tuina when used alongside acupuncture for chronic nonspecific low back pain.

Study Type

Interventional

Enrollment (Estimated)

56

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Singapore, Singapore, 229469
        • Recruiting
        • Novahealth TCM Clinic
        • Contact:
          • Chin Ee Ho
          • Phone Number: +65 84130628
      • Singapore, Singapore, 637551

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

21 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Adults aged 21 to 70 years.
  • At least one primary care visit for back pain within the past 3 to 12 months at either a Chinese medicine or Western medicine clinic.
  • Non-specific, uncomplicated low back pain, as specified in the study protocol.
  • Able to communicate and write in English and/or Chinese.

Exclusion Criteria:

  • Previous acupuncture for back pain within the past 3 months.
  • Low back pain lasting less than 3 months.
  • Mild symptoms, defined in the protocol as a score below 5 on a 0 to 10 pain bothersomeness scale.
  • Specific diseases or pathologies identified as the cause of back pain, including the conditions listed in the study protocol.
  • Previous vertebral column or back surgery.
  • Disabling chronic conditions that may confound treatment effects or interpretation of the data.
  • Contraindications to acupuncture or situations in which its safety has not been confirmed, including clotting disorders, anticoagulant therapy, a cardiac pacemaker, pregnancy or seizure disorder.
  • Deemed unfit for acupuncture and/or robotic Tuina by the treating Chinese medicine physician because of the participant's current medical condition.
  • Current use of long-term medication for pain management and relief, as specified in the study protocol.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Acupuncture Plus Automated Robotic Tuina

Standard acupuncture treatment followed by Automated Robotic Tuina

Participants receive 30 minute standard acupuncture and automated robotic Tuina using the EMMA device, according to the study's standardized operating procedures. Robotic Tuina is applied to the lumbosacral region, hips and lower limbs. The protocol describes an approximately 30-minute robotic Tuina treatment, with the applied force adjusted according to participant feedback within the specified range.

Active Comparator: Acupuncture alone

Standard acupuncture

Participants receive acupuncture according to the study's standardized treatment protocol. The protocol describes needle retention for 30 minutes and specifies the acupuncture points and procedures to be used.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change from baseline in pain intensity. Visual analogue scale.
Time Frame: At baseline, at 8 weeks

A 10-point Numerical Pain Scale (0: no pain, 10: maximum pain) assesses the intensity of pain

At baseline, at 8 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change from baseline in Roland Morris Disability Questionnaire (RMDQ).
Time Frame: At baseline and at 8 weeks

This is a self-reported questionnaire consisting in 24 items reflecting limitations in different activities of daily living attributed to low back pain including walking, vending over, sitting, lying down, dressing, sleeping, self-care and daily activities.

At baseline and at 8 weeks
Change from baseline in Brief Pain Inventory (BPI)
Time Frame: At baseline and at 8 weeks

Pain interference was evaluated using the Pain Interference subscale of the Brief Pain Inventory (BPI). The subscale consists of 7 items assessing how much pain disrupts dimensions of daily living. Each item is scored on a 0 to 10 numeric rating scale. The overall score is calculated as the mean of the 7 items, yielding a final score ranging from a minimum of 0 to a maximum of 10. A higher score indicates a worse outcome (greater pain interference with daily functioning).

At baseline and at 8 weeks
Change from baseline in WHO-QOL (Brief)
Time Frame: At baseline and at 8 weeks

Quality of life was evaluated using the World Health Organization Quality of Life-BREF (WHOQOL-BREF). The scale comprises 26 items assessing 4 domains: Physical Health (7 items), Psychological (6 items), Social Relationships (3 items), and Environment (8 items). Domain scores are calculated by summing the respective items and converting them to a transformed scale. For each domain, scores range from a minimum of 0 to a maximum of 100, where a higher score indicates a better outcome (higher quality of life)

At baseline and at 8 weeks
Change in objective sleep parameters via wearable smart ring
Time Frame: At baseline throughout the 8 weeks, to be tracked the night before and after treatment session.

Assessed using Leadtek smart ring worn on the finger. Evaluated parameters include sleep time, overnight heart rate variability and sleep quality from baseline to week 8

At baseline throughout the 8 weeks, to be tracked the night before and after treatment session.
Change in Technology Acceptance Model (TAM) questionnaire from baseline
Time Frame: At baseline and at 8 weeks

Participant acceptance of automated robotic Tuina, will be measured at baseline and after completion of study covering domains including perceieved usefulness, attitude and behavioural intentions. A 7-point Likert scale was used to measure TAM constructs, where 1 indicated 'strongly disagree' and 7 indicated ' strongly agree'. A higher score reflects better perception of and attitutude towards the technology.

At baseline and at 8 weeks
Incidence of Treatment-Emergent Adverse Events [Safety]
Time Frame: From start of treatment to end of treatment at week 8

Incidence and nature of adverse events during the study.

From start of treatment to end of treatment at week 8

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Principal Investigator: Linda Zhong, Associate Professor, Nanyang Technological University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2025

Primary Completion (Estimated)

December 30, 2027

Study Completion (Estimated)

December 30, 2027

Study Registration Dates

First Submitted

October 29, 2026

First Submitted That Met QC Criteria

November 15, 2026

First Posted (Actual)

November 18, 2026

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 15, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • IRB-2023-1071

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data will not be made available to external researchers. Participant-level data contain confidential health information and will be managed in accordance with the approved study protocol, informed consent requirements, institutional policies and applicable data-protection requirements. Study findings will be disseminated through appropriate scientific publications and other research outputs.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.